



CA CNSX: MBIO

US OTCQB: MBQIF

DE Frankfurt: WF6

INVESTOR PRESENTATION 2026

VOICE IS THE NEW

BIOMARKER FOR HEALTH DIAGNOSTICS

Prediction Technologies for Drug & Alcohol Intoxication Detection

World's first intoxication detection using Voice and AI.

www.mindbiotherapeutics.com



MindBio Therapeutics Corp

Shares on Issue	7,283,063
Reserved for Issuance	5,370,855
Date Commenced Public Trading	5 May 2023
Exchange	Canadian Securities Exchange
Ticker Code	CA CNSX: MBIO US OTCQB: MBQIF DE Frankfurt: WF6
Founded	2019

Leadership Team



Justin Hanka
Founder & CEO
Merchant and investment banking professional, Multiple exits. Justin's investment and work interests are purposely geared to technology assets and having a positive impact on global health.



Gavin Upiter
Non-Executive Chairman
25+ years pharma industry. Founded Generic Health, (sold to Lupin).



Dr Zena Burgess
Non-Executive Director
CEO of Australian Psychological Society. Former CEO of Royal Australian Council of General Practitioners RACGP.



John Dinan
CFO
Experienced public and private company CFO, Private Equity and M&A expert. Ex Olympic Sprinter and record holder



Paul Lopez
Chief Engineer
20+ years working with leading technology companies. Expert in AI and software design. Leads the global engineering team.



Binu Abeysinghe
Head of Speech Engineering
Expert in speech analytics, AI and machine learning. Leads speech analytics team.

Health Diagnostics Using Voice

A health innovation company revolutionizing medical diagnostics with a first mover advantage in drug and alcohol intoxication detection using AI and the human voice.

KEY ACHIEVEMENTS



5 Years

Clinical trials experience



3 RCTs

In controlled substances



85%+

BAC prediction accuracy



50M+

Data samples analyzed

World First Drug & Alcohol Intoxication Detection Using AI and Voice.

"MindBio's lead technology program is the development of a drug and alcohol intoxication predictive software using the **Voice** and AI."

THE CHALLENGE

Detecting Drug & Alcohol Intoxication at Scale. Preventing Unnecessary Harm



Late Detection Elevates Risk

Physiological decline detected too late leads to unnecessary harm. Heavy drinking for example elevates suicide risk 10-20x among the vulnerable. Impaired driving causes accidents.



Current Diagnostic Systems Not Scalable

In drug and alcohol intoxication detection, the current solutions are personally invasive, slow, time consuming, expensive and not scalable. There is an opportunity for significant harm prevention by introducing solutions at scale.

The Cost

\$1.6 Trillion

Global alcohol harm cost

10-20x

Suicide risk increase

40-50%

Suicide involves alcohol.

THE OPPORTUNITY

Harm Prevention using Voice Diagnostics and AI.



Voice as an early warning tool.

The voice can be reliably used for early detection and prevention of harm. If we can screen for drug and alcohol intoxication using voice, we can scale technologies in the workplace, in call centres, in public places for early warning and prevention.

The Impact

- Saved Lives
- Better Productivity
- Improved Performance
- Accident Prevention
- Cost Reduction

Drug and Alcohol Detection. Prevention through early warning tools deployable at scale.

MARKET OPPORTUNITY

Intersection of Digital Health, Telehealth, Drug and Alcohol Harm and AI



TARGET DEPLOYMENT SEGMENTS

- **Call Centres**
Suicide prevention, insurance fraud
- **Law Enforcement**
BAC testing, social order
- **Workplace Safety**
Onsite & remote BAC verification
- **Education**
Drink driving deterrence

OUR SOLUTION

Voice AI Drug & Alcohol Prediction

A multi-layer system built on **clinical trials data and population level data** and powered by AI, voice analytics and other biomarkers. Voice can be used at scale for drug and alcohol intoxication detection.

- ✓ Binary classification model for intoxication detection
- ✓ Blood alcohol concentration (BAC) prediction model
- ✓ Speech analytics & voice biomarker analysis
- ✓ Behavioral cognition assessment
- ✓ Real-time health prediction & early warning

ACCURACY

85%


BAC Prediction Accuracy

Within $\pm 0.001\%$ BAC range

88%

Intoxication Detection Accuracy

Binary classification model



CORE TECHNOLOGY

Voice Analysis as a Health Prediction Tool

AI and ML takes a deep dive into the sound frequencies of our voice to make predictions about health.

1 Feature Extraction


Algorithm extracts **143 engineered features** from voice recordings

2 Mel Spectrogram Analysis

Complete Mel Spectrogram processed over AI to map and predict physiological states

3 Health Prediction

Detect changes deep within voice frequencies to predict internal physiological states



CONSUMER DEPLOYMENT

World's First Voice-Activated BAC Estimator

AI-powered blood alcohol estimation over a smartphone using voice and biomarker analysis

50M+

Analyses millions of data points

20,000+

Tests conducted



Performance Impairment Analysis

Predicts reaction distance and stopping distance to illustrate drink driving risks

Sober
Reaction Distance
8.7m




+30%

Drinking
Reaction Distance
11.3m

app.booze-ai.com

World's first intoxication detection using Voice, AI and a
Smartphone



Edge AI Voice Drug & Alcohol Detection Kiosks

Workplace Health & Safety Intoxication Testing

- Mining Industry
- Aviation Industry
- Construction Industry

Testing at SCALE in zero tolerance regulated industries



WORKPLACE HEALTH AND SAFETY

Detecting Drug & Alcohol Use in the Workforce

Drug & Alcohol intoxication detection is problematic in workplaces that are mandated to conduct testing. The tests are personally invasive. Eg. Saliva, blood, urine plus breath testing, these types of tests can only be conducted randomly and therefore are not scalable across the workforce.

MindBio is developing an enterprise platform for use in the mining industry, aviation industry and construction industry, for flexible deployment and use at workplace entry as a first line screening tool. It's geared to improving safety, reducing costs and saving lives.

MINING INDUSTRY DEPLOYMENT



AVIATION INDUSTRY DEPLOYMENT



CONSTRUCTION INDUSTRY DEPLOYMENT



VALIDATION

Traction & Recognition

88%

Binary classification accuracy
On/off Alcohol Detection

85%

BAC prediction Accuracy
 $\pm 0.001\%$ precision

50M+

Data Samples
Human trial data

20K+

Tests Conducted
Real-world validation

Featured In



Awards & Recognition



Company of the year

Microdose Awards 2022



Entrepreneur of the year

Microdose Awards 2022



Innovator of the year

Microdose Awards 2022




AI Innovator – Healthcare

Australian AI awards 2025 finalist

Listed on **CNSX:MBIO**
Frankfurt: **WF6**
OTCQB: **MBQIF**

PRODUCT ROADMAP



R&D

Complete

- 3 RCTs completed
- 1 Open Label trial completed
- Voice analytics research
- Algorithm development



Consumer App

Launched

- Launch: app.booze-ai.com
- World's first voice BAC
- Consumer-facing product



Enterprise Deployment

In Development

- Law enforcement
- Workplace safety – Mining, Aviation Industry
- Regulatory compliance



Telehealth

In Development

- Suicide risk assessment
- Call center integration
- Insurance applications



Disease Prediction

In Planning

- Predicting internal disease states
- Early warning signals
- Personal health management
- Clinical triage



Health Optimization

In Planning

- Performance optimisation
- Performance biomarker identifiers
- Non-invasive mobile health assessment

Proprietary AI Models: Binary Classification (88% accuracy) + BAC Prediction (85% accuracy)

LET'S CONNECT

Invest in the Future of Health Diagnostics

Join us in building prediction tools for optimised health outcomes



Justin Hanka

Chief Executive Officer

 +61 433 140 886

 justin@mindbiotherapeutic.com

 mindbiotherapeutics.com

 LinkedIn

Disclaimer

Caution Regarding Forward-Looking Statements:

Certain statements in this document relating to expected future performance ("forward-looking statements"). The words or phrases "would be", "will allow", "intends to", "will likely result", "are expected to", "will continue", "is anticipated", "estimate", "project", or similar expressions, or discussions of strategy or of plans, are intended to identify important factors that could cause the Company's actual results to differ materially from those projected in these forward-looking statements. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result", "are expected to", "will continue", "is anticipated", "estimate", "intend", "plan", "projection" and "outlook") are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. In making these forward-looking statements, the Company has assumed that the current market will continue and grow and that the risks listed below will not materially adversely affect the forward-looking statements. Some of the material factors or assumptions used to develop forward-looking statements include: the effects of general economic conditions, the success of the operations and strategies, the estimation of the Company's operation costs and its ability to generate revenue, use of funds, intentions to further develop, market and promote its operations by expansion of its merchant base and industries served in Australia; strategy for customer retention, growth, service development, market position and financial results, the success of marketing and sales efforts of the Company, the Company's efforts to attract and retain customers; the financial results of the Company, including future results of operations, the expected cash flows and sources of revenues and capital; the market future enhancements; unanticipated cash needs and the possible need for additional financing and the adoption of governance policies, committees and practices.

By their nature, forward-looking statements involve numerous assumptions, inherent risks and uncertainties, both general and specific, which contribute to the possibility that the predicted outcomes may not occur or may be delayed. The risks, uncertainties and other factors, many of which are beyond our control, that could influence actual results include, but are not limited to; a downturn in general economic conditions; the ability of the Company to continue to generate revenue and to distribute its products profitably; competition from other payment process providers who are well established with the financial capacity to overwhelm the ability of the Company to operate in Australia; security risks; increasing costs of being a publicly traded company, the possibility that our services may become further regulated; the effectiveness and efficiency of our operations and services; the volatility of stock markets; the possibility of labour disruptions; litigation; legislation; income tax matters; regulatory environment; and the post share price following listing; liquidity (the inability to secure additional financing); the Company's intention not to pay dividends in the near future; claims, lawsuits and other legal proceedings and challenges; conflict of interest with directors and management, and other factors beyond the Company's control.

Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement, to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events.

This document is not a product disclosure statement, investment statement, prospectus, disclosure document or offer document and is not offering any securities or financial products in MindBio Therapeutics Corp and it has not been lodged with ASIC or any other securities regulator in any jurisdiction. The distribution of this document outside of Australia and New Zealand may be restricted by law or regulation.

Recipients are required to inform themselves about, and to observe, any such restrictions in accordance with section 949A of the Corporations Act 2001 (Aust), any recipient of the information contained in this document should note that information is general advice in respect of a financial product and not personal advice and is directed at and has only been prepared for the purposes set out in this document. In providing the general advice, MindBio Therapeutics Corp has not considered the objectives, financial situation or needs of any recipient should note that: (a) the advice has been prepared without taking into account the recipient's objectives, financial situations or needs; and (b) because of that, the recipient should, before acting on the advice, consider the appropriateness of the advice, having regard to the recipient's objectives, financial situation and needs. Although information contained in the document which is derived from publicly available sources, MindBio Therapeutics Corp assumes no responsibility for updating any advice or recommendation contained in this document or for correcting any error or omission which may become apparent after the document has been issued. MindBio Therapeutics Corp and any of its affiliates, or its officers, employees or agents accept no liability whatsoever for any direct, indirect, special or consequential losses arising from the use of this document. By statute cannot be excluded. MindBio Therapeutics Corp, its employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, consequential or otherwise) suffered by the recipient of this document or any other person. Recipients should seek their own financial advice in respect of the financial products referred to in this document. MindBio Therapeutics Corp may receive commissions from transactions involving financial products referred to in this document and may hold interests in financial products referred to in this document.